Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPI-003 in Chronic Hepatitis B
NCT06745973Phase 1Not yet recruiting
- Sponsor
- Epigenic Therapeutics
- Start
- Dec 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EPI-003 in Chronic Hepatitis B (CHB), sponsored by Epigenic Therapeutics. Primary endpoint: Treatment-Emergent Adverse Events at 28 days. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
EPI-003
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT06745973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06745973.